Thao P Dang

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers
    Jun Konishi
    Division of Hematology and Medical Oncology and Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Cancer Res 67:8051-7. 2007
  2. ncbi Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice
    Thao P Dang
    Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
    Oncogene 22:1988-97. 2003
  3. ncbi Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers
    Nobuhiro Haruki
    Division of Hematology, Allergy/Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer Res 65:3555-61. 2005
  4. ncbi Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer
    Luping Lin
    Department of Cancer Biology, Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer Res 70:632-8. 2010
  5. ncbi A training-testing approach to the molecular classification of resected non-small cell lung cancer
    Noboru Yamagata
    Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838, USA
    Clin Cancer Res 9:4695-704. 2003
  6. ncbi Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
    Kevin Vo
    College of Pharmacy, The University of Tennessee, Memphis, TN, USA
    Mol Cancer 10:138. 2011
  7. ncbi VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    David P Carbone
    Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States
    Lung Cancer 69:337-40. 2010
  8. ncbi Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007

Research Grants

  1. MOLECULAR CLONING OF A T(15;19) IN LUNG CANCER CELL LINE
    Thao Dang; Fiscal Year: 2005
  2. Targeting Notch3 in Lung Cancer
    Thao Dang; Fiscal Year: 2007

Collaborators

Detail Information

Publications8

  1. ncbi Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers
    Jun Konishi
    Division of Hematology and Medical Oncology and Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Cancer Res 67:8051-7. 2007
    ..In conclusion, these results support the hypothesis that inhibition of Notch activation using a gamma-secretase inhibitor represents a potential new approach for the targeted therapy of lung cancer...
  2. ncbi Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice
    Thao P Dang
    Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
    Oncogene 22:1988-97. 2003
    ....
  3. ncbi Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers
    Nobuhiro Haruki
    Division of Hematology, Allergy/Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer Res 65:3555-61. 2005
    ..These observations support a role for Notch3 signaling in lung cancer, and one potential mechanism of maintaining the neoplastic phenotype is through the modulation of the EGF pathway...
  4. ncbi Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer
    Luping Lin
    Department of Cancer Biology, Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer Res 70:632-8. 2010
    ..These findings rationalize a mechanistic approach to lung cancer treatment based on Notch3 receptor-targeted therapeutic development...
  5. ncbi A training-testing approach to the molecular classification of resected non-small cell lung cancer
    Noboru Yamagata
    Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838, USA
    Clin Cancer Res 9:4695-704. 2003
    ....
  6. ncbi Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
    Kevin Vo
    College of Pharmacy, The University of Tennessee, Memphis, TN, USA
    Mol Cancer 10:138. 2011
    ..The mounting evidence supporting a role for Notch in cancer promotion and survival suggests that targeting this pathway alone or in combination with other therapeutics represents a promising therapeutic strategy...
  7. ncbi VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    David P Carbone
    Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States
    Lung Cancer 69:337-40. 2010
    ..We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen...
  8. ncbi Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...

Research Grants2

  1. MOLECULAR CLONING OF A T(15;19) IN LUNG CANCER CELL LINE
    Thao Dang; Fiscal Year: 2005
    ..The support given by this K08 award will allow Dr. Dang to build on her existing knowledge and promote her transition to an independent investigator in a highly competitive environment. ..
  2. Targeting Notch3 in Lung Cancer
    Thao Dang; Fiscal Year: 2007
    ..These proposed studies will potentially identify Notch3 as a target for intervention and provide insights into the mechanism of Notch3-related lung cancer pathogenesis. ..